Roche/Genentech Partnering Team: One Face For The World To See

An Interview With Roche Pharma Partnering Head For Neuroscience, Ophthalmology And Rare Diseases

Thomas Zioncheck, global head of neuroscience, ophthalmology and rare diseases, Roche Pharma Partnering, talks to In Vivo about Roche and Genentech’s united partnering group, 2019 successes, and highlights ahead for the big pharma’s neuroscience pipeline.

Zioncheck_Tom_1200.jpg
Thomas Zioncheck

Roche has been praised for its handling of the acquisition of biotech company Genentech Inc., which it has managed to keep at an arm’s length and in which it has continued to foster a biotech spirit. Over a decade ago, in 2009, Roche purchased full ownership of Genentech for $46.8bn, however it had owned a majority stake in the company since 1990.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo